검색
Inhibikase Therapeutics Inc
IKT관심 목록에 추가
1.990USD
+0.050+2.58%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
262.74M시가총액
손실P/E TTM
자세한 내용은 Inhibikase Therapeutics Inc 회사
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc 정보
종목 코드 IKT
회사 이름Inhibikase Therapeutics Inc
상장일Dec 23, 2020
CEOIwicki (Mark T)
직원 수15
유형Ordinary Share
회계 연도 종료Dec 23
주소1000 N. West Street, Suite 1200
도시WILMINGTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호19801
전화13022953800
웹사이트https://www.inhibikase.com/
종목 코드 IKT
상장일Dec 23, 2020
CEOIwicki (Mark T)
Inhibikase Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
자주 묻는 질문
Inhibikase Therapeutics Inc의 상위 5대 주주는 누구인가요?
Inhibikase Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Dr. Christopher H. (Chris) Cabell, M.D.
Inhibikase Therapeutics Inc(IKT)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Inhibikase Therapeutics Inc의 주식을 보유한 기관은 총 152곳이며, 이들이 보유한 주식의 총 가치는 약 103.21M로 전체 발행 주식의 78.17%를 차지합니다. 이는 2025Q4 대비 43845693.00 증가한 수치입니다.